The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAptitude Regulatory News (APTD)

Share Price Information for Aptitude (APTD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 307.00
Bid: 301.00
Ask: 310.00
Change: 3.00 (0.99%)
Spread: 9.00 (2.99%)
Open: 307.00
High: 307.00
Low: 307.00
Prev. Close: 304.00
APTD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Notice of Results

6 Jul 2017 07:00

RNS Number : 2365K
Microgen PLC
06 July 2017
 

6 July 2017

 

MICROGEN plc ('Microgen' or 'Group')

 

TRADING UPDATE AND NOTICE OF RESULTS

 

 

Ahead of announcing Interim Results for the six months ended 30 June 2017 on 24 July 2017, Microgen (MCGN.L), a leading provider of business critical software and services, today issues the following update on trading for the financial year to date.

The Group has made excellent progress in the first half of 2017 resulting in a financial performance ahead of the Board's original expectations for the period whilst maintaining margins consistent with the prior year. The Group's two businesses are successfully executing their declared strategy with Aptitude Software delivering strong organic growth and Microgen Financial Systems successfully continuing on its transition towards a business focused on the Trust & Fund Administration ('T&FA') market.

A key highlight for the Group is the continued new business wins that have driven growth in Aptitude Software's recurring revenue base. Since 30 June 2016, the recurring revenue in Aptitude Software has increased 42% to £15.0 million as at 30 June 2017 (H1, 2016: £10.6 million and 31 December 2016: £12.6 million). There has also been exceptional growth in demand for Aptitude Software's implementation services in the first half of the year as a number of clients progress towards going live with the Aptitude Revenue Recognition Engine ('ARRE'). Upon completion of the half year the Board has reviewed the on-going demand for Aptitude Software's implementation services and, whilst clients' requirements continue to evolve, the Board is now confident that the exceptional level of demand experienced in the first six months of the year will continue throughout 2017, leading to a financial performance for the Group significantly ahead of the Board's expectations for the year. 

Opportunities for Aptitude's existing software and its new products provide the business with confidence for future years. Partners are becoming an increasingly important channel for new business, and as they provide a growing proportion of resources for new implementations, and as a number of the larger ARRE projects are completed, the exceptional level of demand for services experienced in 2017 is expected to moderate in 2018.

Microgen Financial Systems has maintained its focus on the T&FA market within the wealth management sector. The acquisition of Primacy Corporation in February 2017, a competitor in the T&FA market, represented the fifth acquisition since December 2014 and further strengthens the position of the business in this market. As a result of this focus T&FA revenues now represent approximately 60% of Microgen Financial Systems' H1 2017 revenue (H1, 2016: 51%), compared to 33% at the beginning of this transition in 2014.

 

Contacts

Ivan Martin, Chairman 020-7496-8100

Philip Wood, Chief Financial Officer

 

James Melville-Ross / Darius Alexander 020-3727-1000

FTI Consulting

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUGUUGMUPMGAA
Date   Source Headline
10th May 20247:00 amRNSTransaction in Own Shares
8th May 20247:00 amRNSNotification of Major Holdings
8th May 20247:00 amRNSTransaction in Own Shares
7th May 20247:00 amRNSTransaction in Own Shares
3rd May 20247:00 amRNSTransaction in Own Shares
1st May 20244:10 pmRNSTotal Voting Rights
30th Apr 20244:46 pmRNSGrant of awards under 2020 Deferred Bonus Plan
29th Apr 20247:00 amRNSTransaction in Own Shares
24th Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
17th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares
11th Apr 20247:00 amRNSTransaction in Own Shares
10th Apr 20247:00 amRNSTransaction in Own Shares
9th Apr 20247:00 amRNSNotice of 2024 Annual General Meeting
8th Apr 20247:00 amRNSTransaction in Own Shares
4th Apr 20247:00 amRNSTransaction in Own Shares
3rd Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20241:46 pmRNSTotal Voting Rights
2nd Apr 20247:00 amRNSTransaction in Own Shares
28th Mar 20247:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
28th Mar 20247:00 amRNSTransaction in Own Shares
27th Mar 20247:00 amRNSTransaction in Own Shares
26th Mar 20247:00 amRNSTransaction in Own Shares
25th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 20247:00 amRNSTransaction in Own Shares
21st Mar 20247:01 amRNSAptitude to Accelerate Autonomous Finance
21st Mar 20247:01 amRNSShare buyback programme
21st Mar 20247:00 amRNSAudited Results for Year Ended 31 December 2023
21st Feb 20247:00 amRNSChange of Broker Arrangements
9th Feb 20247:00 amRNSHolding(s) in Company
31st Jan 20247:00 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSFull Year Trading Update and Notice of Results
4th Jan 20247:00 amRNSFynapse Win
30th Nov 20237:00 amRNSAppointment of Chief Executive Officer
12th Oct 20237:00 amRNSHolding(s) in Company
2nd Oct 20232:17 pmRNSGrant of awards
29th Sep 20237:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
21st Sep 20232:28 pmRNSHolding(s) in Company
20th Sep 20239:32 amRNSHolding(s) in Company
7th Sep 202310:15 amRNSGrant of Awards under Performance Share Plan
23rd Aug 20231:21 pmRNSHolding(s) in Company
23rd Aug 20231:15 pmRNSHolding(s) in Company
28th Jul 202312:18 pmRNSHolding(s) in Company
28th Jul 20237:00 amRNSHolding(s) in Company
27th Jul 20231:52 pmRNSHolding(s) in Company
26th Jul 20237:00 amRNSInterim Results
24th Jul 20235:22 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSHolding(s) in Company
19th Jul 20237:00 amRNSDirector Retirement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.